Statistics

Number of Journals6
Number of Issues26
Number of Articles203
Article View27,658
PDF Download17,042
Sefid, F., Khadempar, S., Shamriz, R., Amjadi, N. (2018). CRISPR Gene Editing on Human Embryos. , 1(1), 48-55. doi: 10.18502/wjpn.v1i1.2785
Fatemeh Sefid; Saedeh Khadempar; Roshanak Shamriz; Nooshin Amjadi. "CRISPR Gene Editing on Human Embryos". , 1, 1, 2018, 48-55. doi: 10.18502/wjpn.v1i1.2785
Sefid, F., Khadempar, S., Shamriz, R., Amjadi, N. (2018). 'CRISPR Gene Editing on Human Embryos', , 1(1), pp. 48-55. doi: 10.18502/wjpn.v1i1.2785
Sefid, F., Khadempar, S., Shamriz, R., Amjadi, N. CRISPR Gene Editing on Human Embryos. , 2018; 1(1): 48-55. doi: 10.18502/wjpn.v1i1.2785

CRISPR Gene Editing on Human Embryos

World Journal of Peri and Neonatology
Volume 1, Issue 1, July 2018, Pages 48-55  XML PDF (479.87 K)
DOI: 10.18502/wjpn.v1i1.2785
Authors
Fatemeh Sefid1; Saedeh Khadempar1; Roshanak Shamriz1; Nooshin Amjadi* 2
1Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2Preventative Gynecology Research Center, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background: With the recent development of CRISPR/Cas9 genome editing technology, the possibility to genetically influence the human germline (gametes and embryos) has become a separate technical possibility. As a powerful skill for genome engineering, the CRISPR/Cas9 system has been effectively applied to adjust the genomes of several species. The purpose of this review was to appraise the technology and build concepts for the launch of precise hereditary modifications in early human embryos.
 
Methods: We conducted a systematic review of the related literatures searched from PubMed, Google scholar, Web of Science up to June 30, 2017 and then we extracted the essential data. In this review, we present the brief history and basic mechanisms of the CRISPR/Cas9 system and significant challenges and advances in the field as a comprehensive practical guide to absorbed users of genome editing technologies. We introduce factors that influence CRISPR/Cas9 efficacy which must be addressed before effective in vivo human embryo therapy can be realized .in this review, we highlight the advancements that have been made using CRISPR/Cas9 in relation to Human Embryo.
 
Results and Conclusion: The possibility of CRISPR/Cas9 use in the context of human reproduction, to change embryos, germline cells, and pluripotent stem cells are studied created on the writers' expert belief. We discuss recent developments leading to the operation of Human Embryonic gene therapies in clinical trials and consider the predictions for future advances in this rapidly developing field.

 
Keywords
Gene editing; Gene therapy; Development; Embryo; Reproduction
References
1. Aschheim K. Precision editing in the human embryo. Nat Biotechnol 2017; 35(9): 832.
2. Baumann K. Genome editing: CRISPR-Cas becoming more human. Nat Rev Mol Cell Biol 2017; 18(10): 591.
3. Baumann K. Biotechnology: CRISPR-Cas becoming more human. Nat Rev Drug Discov 2017; 16(9): 601
4. Ledford H. CRISPR fixes disease gene in viable human embryos. Nature 2017; 548(7665): 13-4.
5. Lim GB. Genetics: Human genome editing in heart disease. Nat Rev Cardiol 2017; 14(10): 567.
6. Lim GB. Gene therapy: Human genome editing in heart disease. Nat Rev Genet 2017; 18(10): 580.
7. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25(11): 1298-306.
8. Mali P, Lang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al., RNA-guided human genome engineering via Cas9. Science 2013; 339(6121): 823-6.
9. Suzuki, T., M. Asami, and A.C. Perry, Asymmetric parental genome engineering by Cas9 during mouse meiotic exit. Scientific Reports 2014; 4: 7621.
10. Tang L, Zeng Y, Du H, Gong M, Peng J, Zhang B, et al. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Mol Genet and Genomics 2017; 292(3): 525-33.
11. Geurts AM, Cost GJ, Freyvert Y, Zeitler B, Miller JC, Choi VM, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. Science 2009; 325(5939): 433.
12. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don't edit the human germ line. Nature 2015; 519(7544): 410-1.
13. Kang X, Huang Y, Yu Q, Chen Y, Gao X, Sun X, et al. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. Journal of Assisted Reproduction and Genetics 2016; 33(5): 581-8.
14. Kim, D, Kim J, Hur JK, Been KW, Yoon S,Kim JS. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nature biotechnology 2016; 34(8): 863.
15. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell 2015; 6(5): 363-72.
16. Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature 2017; 548(7668): 413-9.
17. National Academies of Sciences, Engineering, and Medicine; National Academy of Medicine; National Academy of Sciences; Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations. Human genome editing: Science, ethics, and governance. Washington DC: National Academies Press (US); 2017.
18. Ormond KE, Mortlock DP, Scholes DT, Bombard Y, Brody LC, Faucett WA, et al. Human germline genome editing. Am J Hum Genet 2017; 101(2): 167-76.
19. Strong A, Musunuru K. Musunuru, Genome editing in cardiovascular diseases. Nat Rev Cardiol 2017; 14(1): 11-20.
20. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32(6): 551-3.
21. Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, et al. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013; 13(6): 659-62.
22. Tabebordbar M, Zhu K, Cheng JKW, Chew WL, Widrick JJ, Yan WX, et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016; 351(6271): 407-11.
23. Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. N Nat Biotechnol 2015; 33(5): 538-42.
24. Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J 2014; 281(23): 5186-93.
25. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby, R, Olson EN. Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science 2014; 345(6201): 1184-8.
26. Long C, Amoasii L, Mireault AA, McAnally JR1, Li H, Sanchez-Ortiz E, et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016; 351(6271): 400-3.
27. Ledford H. CRISPR, the disruptor. Nature, 2015; 522(7554): 20.
28. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don’t edit the human germ line. Nature 2015; 519(7544): 410-1.

Statistics
Article View: 56
PDF Download: 20


Contact Us | Help & Support | Site Map

Journal Management System. Designed by sinaweb.